Tempus announces a collaboration with genialis to develop rna-based biomarker algorithms

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced a collaboration with genialis, the rna-biomarker company. the multi-year agreement allows genialis to leverage tempus' multimodal dataset to develop new rna-based algorithms across cancer types. clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment.
TEM Ratings Summary
TEM Quant Ranking